4D pharma to Present at the H.C. Wainwright BioConnect Conference

Rhea-AI Summary

4D pharma plc (NASDAQ: LBPS), a leader in Live Biotherapeutic products, announced that CEO Duncan Peyton and CSO Alex Stevenson will present at the H.C. Wainwright BioConnect Conference, available for on-demand viewing from January 10, 2022, at 7:00 a.m. ET. The presentation will be accessible for 90 days on the company’s website. 4D pharma specializes in developing drugs derived from the microbiome, with six clinical studies underway, including treatments for Irritable Bowel Syndrome and pancreatic cancer, and collaborations with Merck & Co. for vaccine development.

LEEDS, England--(BUSINESS WIRE)-- 4D pharma plc (AIM: DDDD, NASDAQ: LBPS), a pharmaceutical company leading the development of Live Biotherapeutic products (LBPs), a novel class of drug derived from the microbiome, today announced that Duncan Peyton, Chief Executive Officer of 4D pharma, and Alex Stevenson, Chief Scientific Officer of 4D pharma, will present at the H.C. Wainwright BioConnect Conference. The presentation will be available for on-demand viewing starting Monday, January 10, 2022 at 7:00 a.m. ET (12:00 p.m. GMT).

A replay webcast of the presentation will be available via the ‘Events’ section of the 4D pharma website at www.4dpharmaplc.com for 90 days following the presentation.

About 4D pharma

4D pharma is a world leader in the development of Live Biotherapeutics, a novel and emerging class of drugs, defined by the FDA as biological products that contain a live organism, such as a bacterium, that is applicable to the prevention, treatment or cure of a disease. 4D pharma has developed a proprietary platform, MicroRx®, that rationally identifies Live Biotherapeutics based on a deep understanding of function and mechanism.

4D's Live Biotherapeutic Products are orally delivered single strains of bacteria that are naturally found in the healthy human gut. The Company has six clinical studies in progress, namely a Phase II clinical study of Blautix® in Irritable Bowel Syndrome (IBS), a Phase I/II study of MRx0518 in combination with KEYTRUDA® (pembrolizumab) in solid tumors, a Phase I study of MRx0518 in a neoadjuvant setting for patients with solid tumors, a Phase I study of MRx0518 in patients with pancreatic cancer, and a Phase I/II study of MRx-4DP0004 in asthma. Preclinical-stage programs include candidates for CNS disease such as Parkinson's disease and other neurodegenerative conditions. The Company has a research collaboration with MSD, a tradename of Merck & Co., Inc., Kenilworth, NJ, USA, to discover and develop Live Biotherapeutics for vaccines.

For more information, refer to https://www.4dpharmaplc.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220105005019/en/

4D

Duncan Peyton, Chief Executive Officer +44 (0)113 895 0130

Investor Relations ir@4dpharmaplc.com

Singer Capital Markets - Nominated Adviser and Joint Broker +44 (0)20 7496 3000

Philip Davies / James Fischer (Corporate Finance)

Tom Salvesen (Corporate Broking)

Bryan Garnier & Co. Limited - Joint Broker +44 (0)20 7332 2500

Dominic Wilson

Stern Investor Relations

Julie Seidel +1-212-362-1200

Julie.seidel@sternir.com

Image Box Communications

Neil Hunter / Michelle Boxall +44 (0)20 8943 4685

6 Degrees

Lynne Dardanell +1-336-202-9689

ldardanell@6degreespr.com

Source: 4D pharma plc

FAQ

What is the significance of 4D pharma's presentation at the H.C. Wainwright BioConnect Conference?

The presentation will showcase 4D pharma's advancements in Live Biotherapeutic products, focusing on ongoing clinical studies and collaborations.

When can I view 4D pharma's presentation from the conference?

The presentation will be available for on-demand viewing starting January 10, 2022, at 7:00 a.m. ET.

What ongoing studies is 4D pharma conducting related to Live Biotherapeutics?

4D pharma is conducting six clinical studies, including Phase II trials for Blautix® and studies for MRx0518 related to various cancers.

Which major collaborations does 4D pharma have in drug development?

4D pharma has a research collaboration with Merck & Co. to discover and develop Live Biotherapeutics for vaccines.

What is 4D pharma's MicroRx® platform?

MicroRx® is a proprietary platform developed by 4D pharma to identify Live Biotherapeutics based on their function and mechanism.